Outcome of Board Meeting held on 25th May 2026 for approval of audited result for year ended 31 march 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.3 pts more than Nifty Microcap 250 and 9.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Chandra Bhagat Pharma Limited's Board approved the audited financial results for the year ended March 31, 2026. The statutory auditors (M/s AY & Company) issued an unmodified (clean) opinion, confirming the financial statements present a true and fair view. Net Profit before Tax increased significantly to Rs. 410.50 Lakhs from Rs. 116.54 Lakhs in the prior year, representing approximately 252% growth. Operating cash flow turned positive at Rs. 923.57 Lakhs compared to negative Rs. 570.89 Lakhs in FY25. Total equity grew to Rs. 3,312.65 Lakhs from Rs. 2,996.91 Lakhs. However, total assets decreased to Rs. 9,420.58 Lakhs from Rs. 10,153.04 Lakhs, while trade receivables increased to Rs. 5,461.70 Lakhs from Rs. 3,594.55 Lakhs.
The clean audit opinion and strong profit growth are positive for shareholders. The turnaround in operating cash flow from negative to positive indicates improved operational efficiency. However, rising trade receivables and shrinking total assets warrant monitoring.